Caligan Partners LP

Position in TNGX — Tango Therapeutics, Inc.

CIK 1727492 NEW YORK, NY

Position in TNGX

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$50,392,054

+$17,345,185 QoQ

Shares Held

2,408,798

-35.4% QoQ

Ownership

1.67%

of shares outstanding

% of Portfolio

3.56%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2025

2 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

Caligan Partners LP holds $1,086,520,401 across 21 Biotechnology names. TNGX ranks #7 (4.6% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ABVX	Abivax S.A.	1,461,924	$162,785,237
2	RVMD	Revolution Medicines, Inc.	1,652,808	$160,735,578
3	PCVX	Vaxcyte, Inc.	2,060,719	$119,748,381
4	XENE	Xenon Pharmaceuticals Inc.	1,393,027	$81,004,520
5	MLYS	Mineralys Therapeutics, Inc.	2,772,654	$75,111,196
6	EXEL	Exelixis, Inc.	1,553,262	$66,619,407
7	TNGX	Tango Therapeutics, Inc. This page	2,408,798	$50,392,054
8	TYRA	Tyra Biosciences, Inc.	1,276,968	$48,907,874

2 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$50,392,054	2,408,798	-35.4%	Shares	Sole	2026-05-15
2025-12-31	$33,046,869	3,729,895	—	Shares	Sole	2026-02-17
No filing history on record for this holder in this stock.